Eurosurv. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications

[tetano]

• Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications
  
  
• Saverio Caini[SUP]1[/SUP] , Federica Bellerba[SUP]2[/SUP] , Federica Corso[SUP]2[/SUP] , Ang?lica D?az-Basabe[SUP]2[/SUP] , Gioacchino Natoli[SUP]2[/SUP] , John Paget[SUP]3[/SUP] , Federica Facciotti[SUP]2[/SUP] , Simone Pietro De Angelis[SUP]2[/SUP] , Sara Raimondi[SUP]2[/SUP] , Domenico Palli[SUP]1[/SUP] , Luca Mazzarella[SUP]2[/SUP] , Pier Giuseppe Pelicci[SUP]2,4[/SUP] , Paolo Vineis[SUP]5[/SUP] , Sara Gandini[SUP]2[/SUP]

We reviewed the diagnostic accuracy of SARS-CoV-2 serological tests. Random-effects models yielded a summary sensitivity of 82% for IgM, and 85% for IgG and total antibodies. For specificity, the pooled estimate were 98% for IgM and 99% for IgG and total antibodies. In populations with ≤ 5% of seroconverted individuals, unless the assays have perfect (i.e. 100%) specificity, the positive predictive value would be ≤ 88%. Serological tests should be used for prevalence surveys only in hard-hit areas.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.23.2000980#html_fulltext